Immunomodulatory and anti-fibrotic effects of ganglioside therapy on the cardiac chronic form of experimental Trypanosoma cruzi infection

International Immunopharmacology

Volumn 11, Issue 8, 2011, Pages 1024-1031

  Cutrullis, Romina Andrea ^a   Poklépovich, Tomás Javier ^a   Postan, Miriam ^b   Freilij, Héctor Leon ^a   Petray, Patricia Beatriz ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b Instituto Nacional de Diagnostico e Investigacion de la Enfermedad de Chagas Dr Mario Fatala Chaben   (Argentina)

Author keywords

Chronic infection; Ganglioside treatment; Immunomodulation; Myocardium; Trypanosoma cruzi

Indexed keywords

GAMMA INTERFERON; GANGLIOSIDE GM1; MESSENGER RNA; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; FEMALE; HEART INJURY; HEART MUSCLE; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 84860396946     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.02.022     Document Type: Article

References (41)

1. World Health Organization. Tropical disease research. Twelfth Programme Report of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Disease (TDR); 1999. Geneva, Switzerland.
2. Elizari MV. Chagasic myocardiopathy: historical perspective. Medicina (Buenos Aires) 1999;59:25-40.
3. Hagar JM, Rahimtoola SH. Chagas' heart disease. Curr Probl Cardiol 1995;20: 825-924.
4. Milei J, Storino R, Jorg M, Chiale P, Schetjman D, Sterin-Borda L, et al. Patogenia. In: Storino R, Milei J, editors. Enfermedad de Chagas. Buenos Aires: Doyma Argentina SA; 1994. p. 103-28.
5. Manzullo EC, Chuit R. Risk of death due to chronic chagasic cardiopathy. Mem Inst Oswaldo Cruz 1999;94(Suppl 1):317-20. (Pubitemid 129584519)
6. Pereira Barretto AC, Mady C, Arteaga-Fernandez E, Stolf N, Lopes EA, Higuchi ML, et al. Right ventricular endomyocardial biopsy in chronic Chagas' disease. Am Heart J 1986;111:307-12. (Pubitemid 16107269)
7. Higuchi ML, De Morais CF, Pereira Barreto AC, Lopes EA, Stolf N, Bellotti G, et al. The role of active myocarditis in the development of heart failure in chronic Chagas' disease: a study based on endomyocardial biopsies. Clin Cardiol 1987;10:665-70. (Pubitemid 18012754)
8. Araujo-Jorge TC, Waghabi MC, Soeiro MNC, Keramidas M, Bailly S, Feige JJ. Pivotal role for TGF-β in infectious heart disease: the case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy. Cytokine Growth Factor Rev 2008;19: 405-13.
9. Cunha-Neto E, Nogueira LG, Teixeira PC, Ramasawmy R, Drigo SA, Goldberg AC, et al. Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy. Mem Inst Oswaldo Cruz 2009;104(Suppl I):252-8.
10. Bronia DH, Pereira MI, Luján HD, Fretes RE, Fernández A, Paglini PA. Ganglioside treatment of acute Trypanosoma cruzi infection in mice promotes long-term survival and parasitological cure. Ann Trop Med Parasitol 1999;93(4):341-50. (Pubitemid 29358745)
11. Cossy Isasi S, Fernandeez AR, Paglini P, Bronia DH. GM1 ganglioside induced myocardial restoration and survival of mice with experimental Chagas' disease. Acta Trop 1999;73:295-302. (Pubitemid 29528120)
12. Cossy Isasi S, Rodríguez M, Pereira BMI, Díaz-Luján C, Fretes RE, Haüen DI. Trypanosoma cruzi: altered parasites after in vitro treatment with gangliosides, a therapeutic agent in experimental Chagas' disease. Exp Parasitol 2009;122(3): 218-25.
13. Iosa D, Casadei Massari D, Dorsey FC. Chagas' cardioneuropathy: effect of ganglioside treatment in chronic dysautonomic patients. A randomized, doubleblind, parallel, placebo-controlled study. Am Heart J 1991;122(3 Pt 1):775-85.
14. Mitelman J, Gimenez L, Aparicio NJ, Cortelezzi M. Long-term treatment of chronic chagasic cardioneuropathy with a mixture of gangliosides: effect on evolution of circulating antiGM1 antibodies. J Cardiol 1999;34(4):189-97. (Pubitemid 29510334)
15. Corral RS, Petray PB. CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi. Vaccine 2001;19:234-42. (Pubitemid 30621517)
16. Schijman A, Vigliano CA, Viotti RJ, Burgos JM, Brandariz S, Lococo BE, et al. Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic Chagas heart disease. Am J Trop Med Hyg 2004;70(2):210-20. (Pubitemid 38200528)
17. World Heart Federation Consensus Conferences Definition of Inflammatory Cardiomyopathy (Myocarditis), Marlburg, Germany; 1997.
18. Postan M, Dvorak JA, McDaniel JP. Studies of Trypanosoma cruzi clones in inbred mice. I. A comparison of the course of infection of C3H/HEN- mice with two clones isolated from a common source. Am J Trop Med Hyg 1983;32:497-506. (Pubitemid 13101438)
19. Cutrullis RA, Postan M, Petray PB, Corral RS. Timing of expression of inflammatory mediators in skeletal muscles from mice acutely infected with the RA strain of Trypanosoma cruzi. Pathobiology 2009;76:170-80.
20. Tostes S, Bertolucci Rocha-Rodrigues D, Araujo Pereira G, Rodrigues V. Myocardiocyte apoptosis in heart failure in chronic Chagas' disease. Int J Cardiol 2005;99: 233-7. (Pubitemid 40320795)
21. Higuchi ML, Benvenuti LA, Martins Reiss M, et al. Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovasc Res 2003;60: 96-107. (Pubitemid 38373480)
22. Araújo-Jorge TC, Waghabi MC, Hasslocher-Moreno AM, Xavier SS, Higuchi M de L, Keramidas M, et al. Implication of transforming growth factor-beta1 in Chagas disease myocardiopathy. J Infect Dis 2002;186:1823-8. (Pubitemid 35463516)
23. Waghabi MC, Keramidas M, Calvet CM, Meuser M, Soeiro MNC, Mendonca-Lima L, et al. SB-431542, a transforming growth factor inhibitor, impairs Trypanosoma cruzi infection in cardiomyocytes and parasite cycle completion. Antimicrob Agents Chemother 2007;51(8):2905-10. (Pubitemid 47206229)
24. Bunch TJ, Mahapatra S, Bruce GK, Johnson SB, Miller DV, Horne BD, et al. Impact of transforming growth factor-beta1 on atrioventricular node conduction modification by injected autologous fibroblasts in the canine heart. Circulation 2006;113: 2485-94. (Pubitemid 43948026)
25. Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, Küpper I, et al. Interferongamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol 2007;171(2):463-72. (Pubitemid 47344679)
26. Terasaki F, Ukimura A, Tsukada B, Fujita S, Katashima T, Otsuka K, et al. Enhanced expression of type 1 helper T-cell cytokines in the myocardium of active cardiac sarcoidosis. Circ J 2008;72(8):1303-7.
27. Ritter JT, Tang-Feldman YJ, Lochhead GR, Estrada M, Lochhead S, Yu C, et al. In vivo characterization of cytokine profiles and viral load during murine cytomegalovirus- induced acute myocarditis. Cardiovasc Pathol 2010;19(2):83-93.
28. Ferreira RC, Ianni BM, Abel LC, Buck P, Mady C, Kalil J, et al. Increased plasma levels of tumor necrosis factor alpha in asymptomatic/ "indeterminate" and Chagas disease cardiomyopathy patients. Mem Inst Oswaldo Cruz 2003;98:407-11. (Pubitemid 38030560)
29. Román-Campos D, Duarte HGL, Sales Jr PA, Natali AJ, Ropert C, Gazzinelli RT, et al. Changes in cellular contractility and cytokines profile during Trypanosoma cruzi infection in mice. Basic Res Cardiol 2009;104(3):238-46.
30. Talvani A, Rocha MOC, Ribeiro AL, Correa-Oliveira R, Teixeira MM. Chemokine receptor expression on the surface of peripheral blood mononuclear cells in Chagas disease. J Infect Dis 2004;189:214-20. (Pubitemid 38147244)
31. Gomes JAS, Bahia-Oliveira LMG, Rocha MOC, Busek SCU, Teixeira MM, Santana Silva J, et al. Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients. Infect Immun 2005;73(12):7960-6.
32. Leon JS, Wang K, Engman DM. Captopril ameliorates myocarditis in acute experimental Chagas disease. Circulation 2003;107(17):2264-9. (Pubitemid 36547223)
33. Frangogiannis NG, Entman ML. Targeting the chemokines in myocardial inflammation. Circulation 2004;110:1341-2. (Pubitemid 39238010)
34. dos Santos PVA, Roffê E, Santiago HC, Torres RA, Marino APMP, Paiva CN, et al. Prevalence of CD8+αβ T cells in Trypanosoma cruzi-elicited myocarditis is associated with acquisition of CD62LLowLFA-1HighVLA-4High activation phenotype and expression of IFN-γ-inducible adhesion and chemoattractant molecules. Microbes Infect. 2001 3 971-84. (Pubitemid 32913696)
35. Medeiros GA, Silverio JC, Marino ANMP, Roffe E, Vieira V, Kroll-Palhares K, et al. Treatment of chronically Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect 2009;11(2):264-73.
36. Irani DN, Lin KI, Griffin DE. Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J Immunol 1996;157:4333-40. (Pubitemid 126449350)
37. Monteiro de Castro G, Zanin ME, Ventura-Oliveira D, Vilella CA, Ashimine R, de Lima Zollner. Th1 and Th2 cytokine immunomodulation by gangliosides in experimental autoimmune encephalomyelitis. Cytokine 2004;26:155-63. (Pubitemid 38624628)
38. Kopitz J, von Reitzenstein C, Burchert M, Cantz M, Gabius HJ. Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture. J Biol Chem 1998;273(18):11205-11. (Pubitemid 28204971)
39. Wang J, Lu ZH, Gabius HJ, Rohowsky-Kochan C, Ledeen RW, Wu G. Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J Immunol 2009;182:4036-45.
40. Zuñiga E, Gruppi A, Hirabayashi J, Kasai KI, Rabinovich GA. Regulated expression and effect of galectin-1 on Trypanosoma cruzi-infected macrophages: modulation of microbicidal activity and survival. Infect Immun 2001;69(11):6804-12. (Pubitemid 32995439)
41. Shen W, Stone K, Jales A, Leitenberg D, Ladisch S. Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J Immunol 2008;180:4425-32.